There are few instances in Clinical Oncology where two regimens of similar efficacy exist for the same tumor type. Since apparently equivalent chemotherapy regimens exist for the treatment of NSCLC, the Goldie and Coldman hypothesis could also be tested in this tumor type. Historically, SWOG conducted a phase III trial randomizing patients between FOMi (5-Fluorouracil/Vincristine/MitomycinC), CAP (Cyclophosphamide/Doxorubicin/Cisplatin) and a third arm FOMi/CAP, which alternated the two combinations. Response rates were 26%, 17% and 22%, respectively, and were not statistically significantly different (P=0 .247). Survival was reported as 20, 24 and 23 weeks, respectively. Statistically survival of FOMi/CAP treated patients was superior to FOMi treated (P=0.024) but not CAP treated (P=0.23) patients (7). Since then, several studies have attempted to improve upon the response rate and survival in advanced NSCLC by using regimens with alternating cycles of non-cross-resistant therapy (8,9,10,11). These regimens yielded overall response rate of 21-49%, median survival of 20-48 wks with acceptable toxicity.